Zacks Investment Research downgraded Nevro Corp (NASDAQ:NVRO) to Hold in a report released today.
- Updated: October 17, 2016
Zacks Investment Research has downgraded Nevro Corp (NASDAQ:NVRO) to Hold in a report released on 10/18/2016.
Previously on Wednesday October 05, 2016, Zacks Investment Research reported about Nevro Corp (NASDAQ:NVRO) raised the target price from $0.00 to $110.00. At the time, this indicated a possible upside of 0.12%.
Yesterday Nevro Corp (NASDAQ:NVRO) traded -0.89% lower at $98.02. The company’s 50-day moving average is $97.95 and its 200-day moving average is $80.60. The last stock close price is up 21.62% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 283,938 shares of the stock were exchanged, down from an average trading volume of 479,335
See Chart Below
Nevro Corp has a 52 week low of $36.51 and a 52 week high of $106.93 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $80.67 with 1 firm rating the stock a strong buy, 5 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Nevro Corp (NASDAQ:NVRO)
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company's Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals. The Company's Senza is designed to create electrical impulses from 2 hertz to 10 kilohertz (kHz), including its HF10 therapy. HF10 therapy delivers waveforms at 10 kHz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.